We investigated whether rimonabant, a type 1 cannabinoid receptor antagonist, reduces visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) in dogs maintained on a hypercaloric high-fat diet (HHFD). To determine whether energy expenditure contributed to body weight changes we also calculated resting metabolic rate. Twenty male dogs received either rimonabant (1.25 mg · kg -1 · d -1 , orally; n = 11) or placebo (n = 9) for 16 weeks, concomitant with a HHFD. VAT, SAT and non-fat tissue were measured by magnetic resonance imaging. Resting metabolic rate was assessed by indirect calorimetry. By week 16 of treatment, rimonabant dogs lost 2.5% of their body weight (P = 0.029), while in placebo dogs body weight increased by 6.2% (P < 0.001). Rimonabant reduced food intake (P = 0.027), concomitant with a reduction of SAT by 19.5% (P < 0.001). In contrast with the VAT increase with placebo (P < 0.01), VAT did not change with rimonabant. Non-fat tissue remained unchanged in both groups. Body weight loss was not associated with either resting metabolic rate (R 2 = 0.24; P = 0.154) or food intake (R 2 = 0.24; P = 0.166). In conclusion, rimonabant reduced body weight together with a reduction in abdominal fat, mainly due to SAT loss. Body weight changes were not associated with either resting metabolic rate or food intake. The findings provide evidence of a peripheral effect of rimonabant to reduce adiposity and body weight, possibly through a direct effect on adipose tissue.
Introduction
The association among body fat accumulation, insulin resistance and other metabolic disorders, including type 2 diabetes, is well documented (3, 13, 19, 26) . Obesity is a known risk factor for cardiovascular diseases, cancer, insulin resistance and the development of type 2 diabetes, this latter being the 5 th leading cause of death in the United States (American Diabetes Association) and a growing problem worldwide (46) .
Of recent interest in this regard is the cannabinoid system and its role in the regulation of metabolism, body weight and energy expenditure (8, 33) . One of the compounds which can affect obesity is rimonabant, a selective type 1 cannabinoid receptor (CB1R) antagonist (7, 34, 39) . Rimonabant has been reported to decrease appetite and body weight, though the former effect seems to be transient and might not explain the sustained body weight loss (9, 11, 35, 36) .
Studies conducted in rodents have shown that rimonabant decreases adiposity in different regions of the body. Obese mice treated with rimonabant decreased epididymal, peri-renal and lumbar fat depots (36) after 40-days of treatment. Similarly, rats treated with rimonabant for 10-14 days showed a decrease in total body fat (9) and subcutaneous, retroperitoneal, mesenteric and epididymal fat (11) . A recent report demonstrates a significant reduction in visceral fat in mice treated with rimonabant for 6 weeks concomitant with a candy diet (16) . However, what constitutes true visceral fat in the mouse model remains to be clearly identified.
To date, human studies testing the effect of rimonabant on obesity have demonstrated a significant reduction in waist circumference (7, 34, 43) , which serves as a surrogate of Effect of Rimonabant on Abdominal Fat visceral adiposity. Increased fat accumulation in the abdomen, particularly visceral adiposity, has been associated with a variety of metabolic abnormalities including insulin resistance and cardiovascular diseases (4, 14, 30, 42, 44) . Interestingly, dogs, unlike rodents, have the typical abdominal fat compartments seen in humans, i.e., clearly defined as visceral and subcutaneous fat depots. These compartments are enhanced in dogs after a prolonged high-fat diet (24, 25) and are associated with the canine metabolic syndrome. Thus, it is of interest to study the effects of a cannabinoid antagonist in an animal model with fat compartments similar to humans in order to gain insight into possible therapies for fat deposition.
In this study, we monitored the effect of rimonabant treatment on fat distribution in the abdominal trunk of dogs maintained on a high-fat diet. In addition, since obesity results from an imbalance between caloric intake and energy expenditure, and resting metabolic rate is the major component of energy expenditure, we examined whether resting metabolic rate contributes to the body-weight loss induced by rimonabant.
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Materials and methods
Animals.
A total of 20 male adult mongrel dogs were included in this study. Animals were housed in kennels at the vivarium of the Keck School of Medicine at the University of Southern California. This study was approved by the ethics committee of the University of Southern California.
Induction of fat accumulation. Dogs were initially maintained on a standard diet for a 3-week acclimation period (3885 kcal/d, 39.4% carbohydrates, 33.2% fat, 27.4% proteins). Food was presented from 0900-1200 h, daily. To induce fat accumulation we switched from the standard diet to a hypercaloric high-fat diet (HHFD), which consisted of 5527 kcal/d (27.7% carbohydrates, 53.0% fat, 19.3% proteins), also presented from 0900-1200 h, daily. We have previously reported that 6 weeks is an adequate period to observe significant increases in adiposity (24, 25) and body weight (23) . Thus, the HHFD was maintained for a minimum of 6 weeks (9±2 wks) period prior to any drug treatment.
Rimonabant treatment. After the initial fat feeding period of, animals were randomly segregated into two groups, rimonabant (n = 11) or placebo (n = 9 Resting metabolic rate. In a subset of dogs (rimonabant, n = 7; placebo, n = 5) we assessed resting metabolic rate by indirect calorimetry. The calorimetric chamber used consisted of a standard dog kennel adapted for the experiments. All dogs were acclimated to the chamber three weeks prior to the initiation of the protocol. Dogs were fasted for at least 12 hours prior to each experiment. We assessed resting metabolic rate at weeks 0, 2, groups. General linear model was used to determine multiple correlation (R) between variables measured repeatedly throughout the study. All the analyses were done using Statistica (StatSoft Inc., Tulsa, OK, USA). Differences were assumed to be significant if the P value was less than 0.05.
Results
Initial induction of fat accumulation (weeks -6 to 0). The initial 6 weeks of HHFD resulted in a 7.1% increase in body weight (n = 20) from 29.6 ± 0.8 to 31.8 ± 1.0 kg (P < 0.001). These changes were accompanied by a 35.8% increase in total fat in the abdominal trunk (733.3 ± 58.5 to 995.5 ± 90.8 cm 3 , P < 0.001) with no changes in nonfat tissue (P = 0.166). There were increases in both VAT (28.1 %, P < 0.001) and SAT (66.8%, P < 0.001), with a predominance of SAT accumulation in absolute numbers (145.7 ± 32.0 vs. 116.6 ± 21.0 cm 3 , SAT and VAT, respectively) ( Fig. 1) . The fat percentage of the total tissue increased from 24.9% to 31.5% (P < 0.001).
Effect of rimonabant on body weight and food intake (weeks 0 to 16). By week 16 of treatment and continued HHFD, rimonabant treated dogs lost 2.8% of their body weight while placebo dogs increased their body weight by 6.5%. However, body weight was not different between groups (P = 0.156). In the rimonabant group we observed transient decreases in food intake, at week 2 (P < 0.001) and at week 16 (P = 0.027). Placebo group showed no changes in food intake throughout the study . When we normalized food intake to body weight we found a significant difference between groups only at week 2 (65.1 ± 4.1 vs. 81.2 ± 3.0 kcal · kg
, rimonabant vs. placebo, respectively; P = 0.007) ( Table 1) .
Effect of rimonabant on the abdominal fat composition. Fat changes in the abdominal trunk from representative dogs in each group are shown in Fig. 2 . The body weight loss Effect of Rimonabant on Abdominal Fat seen in the rimonabant group was consistent throughout the study, and occurred concomitant with a loss of total fat in the abdominal trunk . Interestingly, VAT remained unchanged in the rimonabant group, while SAT decreased consistently from week 6 to the end of the study. Conversely, placebo group showed a progressive increase in total fat, including VAT and SAT, reaching significant changes in the last 4 weeks of the study ( Table 1) . Trends of total fat, VAT and SAT changes in both groups throughout the study are shown in Fig. 3 .
At the end of the study, total fat, VAT and SAT, but not non-fat tissue, expressed as percent changes of the baseline (Δ), were significantly different between groups (rimonabant versus placebo, Δ total fat: -14.0 vs. 26.2%, P < 0.001); Δ VAT: -9.8 vs. The decrease in body weight induced by rimonabant was significant after 2 weeks of treatment until the end of the study (Fig. 4A) . However, the dogs exhibited only a transient decrease in food intake at week 2 (Fig. 4B ). This transience in the effect of RIM on food intake has been consistently reported in rodent studies (9, 11, 35, 36) .
Importantly, we did not find a correlation between food intake and body weight changes.
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Together, these results suggest that food intake alone cannot explain the profound effect of RIM to reduce weight.
The observation that rimonabant induced a preferential loss of SAT, rather than VAT, does not appear to be in concordance with the notion that adipocytes from VAT have a higher basal lipolytic rate than adipocytes from SAT. However, it must be noted that in the present study, fat feeding was maintained throughout the treatment period. We have recently hypothesized that fat accumulates initially in the VAT depot and then spills over into the SAT depot, known as the overflow hypothesis (2). Hence, in the presence of Whether CB1R expression is found in canine fat tissue is largely unknown. However, we have recently shown that rimonabant treatment prevents the accumulation of large adipocytes (>100 μm) in subcutaneous and omental fat in dogs fed a HHFD (17) .
It has been reported that increased fat accumulation in adipocytes lead to an increase in lipolysis (47). While we found an increase in the number of large adipocytes (>75 µm)
with fat feeding, we did not observe any differences in basal lipolysis measured in vitro (data not shown). These observations lead us to speculate that there is a threshold in which lipid accumulation in adipocytes must reach in order to observe changes in Effect of Rimonabant on Abdominal Fat lipolytic activity. Consistent with this notion is a recent report in rats that demonstrate no change in basal lipolysis in high fat fed rodents at a time when mesenteric and retroperitoneal fat pads are significantly increased (5). However, after prolonged periods of fat feeding and consequently increased fat accumulation, differences in lipolytic activity were noted. Moreover, some studies suggest that the antiobesity effects of rimonabant are due to increased lipolysis, yet we observe no differences between the two groups. The molecular mechanism as to how rimonabant prevents visceral fat accumulation and reduces subcutaneous fat content remains to be elucidated. Clearly, the roles of lipogenesis, LPL activity and re-esterification rates must be taken into account. A potential mechanism may be gleaned from mouse studies that demonstrate inhibition of lipid accumulation into adipocytes by blocking pre-adipocyte proliferation (12) .
An alternative mechanism for the reduction in body adiposity and weight loss may be attributed to changes in energy expenditure. Energy expenditure has been shown to be enhanced with rimonabant treatment. Since resting metabolic rate represents the largest component of total energy expenditure (29, 37), we examined whether body weight loss induced by rimonabant was dependent on resting metabolic rate changes. In a subset of dogs we conducted a study to determine whether increases in energy expenditure could explain the body weight changes. Surprisingly we found no significant changes on resting metabolic rate during the study (Fig. 4C) . Moreover, there was no association between resting metabolic rate and body weight changes. These results suggest that other components of total energy expenditure might explain the body weight loss (29) (i.e.
physical activity and adaptive thermogenesis). It has been reported that rimonabant increases grooming (18) and scratching activity (18, 28) in rodents. In addition, it has Effect of Rimonabant on Abdominal Fat been shown that acute (28) and chronic (15) administration of rimonabant increases total energy expenditure in rats. Physical activity was not monitored in this study. However, weekly core body temperatures (data not shown) in the dogs remained invariable throughout the study, indirectly suggesting that the body heat production was not altered.
Thus, the reduction of body weight may be due to changes in spontaneous physical activity.
Clinical studies aimed to determine the effect of other anti-obesity drugs in combination with a low-calorie diet on abdominal fat distribution, either by computed tomography or MRI, demonstrate a decrease in both VAT and SAT compartments.
Orlistat, an inhibitor of pancreatic lipase (40) and sibutramine, a blocker of serotonin and norepinephrine reuptake, (20, 21, 48) were able to significantly reduce abdominal fat content in obese subjects. However, unlike our study, the aforementioned studies are treatment therapies in combination with a low-calorie diet. In the face of continued fat feeding, it may be difficult to see a true reduction in visceral fat, particularly if fat is preferentially deposited in this depot.
It has been reported that over-expression of adiponectin in mice resulted in expansion of SAT and was associated with an improvement of the metabolic profile (22) . In addition, it has recently been reported that transplantation of SAT into the VAT depot improved insulin sensitivity in mice (41) . Apparently, these results might be in conflict with the fact that the effect of rimonabant was more pronounced in SAT. Though, the findings from these studies are interesting, the extrapolation of those results to human obesity is unknown, given the differences in fat distribution and composition between humans and rodents. In fact, if SAT were beneficial, liposuction would significantly Effect of Rimonabant on Abdominal Fat impair the metabolic profile in humans that undergo this procedure. For example, some studies have not shown changes in metabolic parameters after 10-12 weeks of follow-up (27) or within 1-4 years of a significant sustained reduction of SAT (31) . Together, these human studies suggest that SAT does not have a beneficial effect on metabolic disease.
In conclusion, this study provides the first direct evidence of the effect of rimonabant on fat distribution in the abdominal region in a canine model which parallels fat distribution in humans. Chronic treatment with rimonabant resulted in a reduction of body weight and fat content in the abdominal trunk with no changes in non-fat tissue, suggesting a direct effect of rimonabant on adipocytes. In contrast, with the significant increases of both SAT and VAT in placebo, rimonabant prevented additional VAT accumulation and decreased SAT. The reduction in overall body weight was not associated with either resting metabolic rate or food intake changes. However, an increase in spontaneous physical activity cannot be excluded as a possible mechanism to induce weight loss.
These findings provide evidence of a peripheral effect of rimonabant to reduce adiposity and body weight, possibly through a direct effect on adipose tissue. Data are means ± SE. *P < 0.001, compared with week -6. 
Legends for figures
